Legend Biotech / 南京传奇

Legend Biotech appears in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 as the Chinese CAR-T commercialization case behind a multiple-myeloma product developed with Johnson & Johnson / 强生. The episode uses the company to show that CAR-T can become a major pharmaceutical business once strong clinical response moves a product earlier in treatment lines.

The source says the Legend-Johnson & Johnson product reached about $1.9 billion in 2025 sales and moved from fourth-line toward second-line treatment because of efficacy. In the episode, this supports Liu’s claim that blood-cancer CAR-T is constrained less by whether it works than by manufacturing cost and scale.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 adds a more competitive reading. The source says Johnson & Johnson’s multiple-myeloma TCE and combination data can pressure CAR-T expectations, making Legend a case where strong cell-therapy commercialization still has to defend itself against adjacent immune-redirection formats.

Key Claims

• Legend Biotech is used as a proof point that CAR-T can pass the “blockbuster drug” commercial threshold.
• The product-line movement from late-line to earlier-line therapy is presented as the business consequence of strong efficacy.
• The company is a Chinese biotech example inside a field Liu says developed in China and the United States on a near-synchronous timeline.
• Episode 156 adds that TCE competition can affect market expectations even for an established CAR-T commercialization case.

Connections

• Johnson & Johnson / 强生 - commercial partner named in the source.
• CAR-T Cell Therapy and Ex Vivo CAR-T Manufacturing - therapy and manufacturing context for the commercial case.
• China Cell Therapy Regulatory Dual Track - Chinese cell-therapy ecosystem context.
• T-Cell Engagers and Biotech BD Data Validation Phase - modality-competition and follow-up evidence context.